Citius Oncology, Inc. (CTOR) — Cash Flow Quality Index
Citius Oncology, Inc. (CTOR) has a Cash Flow Quality Index of -1.44x as of June 2024. Operating cash flow of $-364.06K is below net income of $252.46K, suggesting accrual-heavy earnings not yet converted to cash. Explore Citius Oncology, Inc. (CTOR) cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Citius Oncology, Inc. Cash Flow Quality Index (2022–2023)
Historical Cash Flow Quality Index for Citius Oncology, Inc. across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Citius Oncology, Inc. total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Citius Oncology, Inc. (2022–2023)
Year-by-year earnings quality comparison for Citius Oncology, Inc.. For live market cap and the full company financial profile, see CTOR company net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | -0.25x | $-601.30K | $2.42 Million | ▼ -97.3% |
| 2022 | -0.13x | $-47.97K | $380.81K | — |